“Pfizer is committed to ensuring adult vaccination is prioritized as a key preventive tool around the globe – thereby helping protect this population from infectious diseases as they age,” continued Silbermann.Currently, Prevenar 13, or Prevnar 13 as it is called in the United States, Canada and Taiwan, is approved in adults 50 years of age and older in more than 70 countries, including Australia, Canada, the European Union, India, Mexico, Russia, Singapore, Turkey and the United States. WHO Prequalification Expands Access Now that Prevenar 13 has received WHO prequalification for its adult 50 years of age and older indication, Pfizer will work with global partners in the international community to help make the vaccine available to these adults, as well as infants and children, at risk of pneumococcal disease globally. As an expression of this commitment, Pfizer is pleased to participate in the Advance Market Commitment (AMC) program, which helps to ensure infants and young children in the world’s poorest countries have access to pneumococcal conjugate vaccines. To meet the growing global demand for Prevenar 13, Pfizer is increasing its manufacturing capabilities to help ensure product supply through a combination of capital investment, process improvements and efficiency measures throughout the supply network. Pfizer is also investing in the development of a preserved, multi-dose vial which, subject to WHO prequalification, is expected to offer an alternative option for developing countries. This additional investment further underscores the company’s commitment to the prevention of pneumococcal disease through vaccination around the world, including in least developed countries. To date, Pfizer has agreed to supply a total of up to 480 million doses of Prevenar 13 through 2023 to infants and young children in the poorest countries of the world under the AMC for pneumococcal vaccination. Prevenar 13 for pediatric use is available in 16 of the 18 countries that have launched national immunization programs with a pneumococcal conjugate vaccine through the AMC.